ATTO
ATTO
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
6
$52.37M
Insider Sales
2
$4.50M
Total Volume
$56.87M
8 transactions
Net Activity
+$47.87M
Net buying
Sentiment Rating
Strong AccumulationCEO Conviction Index
No Recent Signal
Key Drivers
- •Strong buying bias: purchases represent 92% of total transaction value.
- •Cluster buying: 6 unique insiders purchased shares, showing strong alignment.
- •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Walsh Colin
Dir
$12.54M total
Goldman Sachs Group Inc
Former 10% Owner
$12.54M total
Redmile Group, LLC
10%
$10.20M total
Frazier Life Sciences Xi, L.P.
10%
$10.00M total
Venbio Global Strategic Fund Iv, L.P.
10%
$6.50M total
Quick Actions
ATTO has an insider buy conviction of 92%, compared to the Unknown sector buy average of 6%.
Over the last 90 days, corporate insiders at ATTO (ATTO) engaged in a total of 8 transactions reported via SEC Form 4 filings. Among these, 6 were open-market purchases and 2 were sales. The total volume of insider trading reached $56.87M.
The net insider activity for ATTO shows a net buying bias of $47.87M. This activity represents a 92% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Purchase by Walsh Colin (Dir), who traded 585.0K shares valued at $10.29M on Aug 5, 2026.
Attovia Therapeutics Inc. Stock Grades | ATTO
Over 4 million shares underpin venBio’s reported passive stake in Attovia Therapeutics (ATTO).
symbol__ Stock Quote Price and Forecast
Attovia Therapeutics (ATTO) Pulls Back As Investors Ask If The Valuation Still Fits
Attovia Therapeutics (NasdaqGM:ATTO) Stock Forecast & Analyst Predictions
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
FAQs About ATTO Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ATTO.